BioLargo Inc (BLGO)
OTHER OTC:BLGO
Top Page
BioLargo
(OTC:BLGO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.16
▼(-16.32% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held down by weak financial performance—ongoing losses, accelerating cash burn, and a shrinking equity cushion in 2025. Technicals also remain soft with the stock trading below major moving averages. Offsetting factors are modest: management’s 2026 commercialization/validation catalysts and a new flexible financing backstop, but these do not yet outweigh current financial and execution risks.
Positive Factors
Gross margin sustainability
Consistent mid-40% gross margins indicate the company’s product and service economics are structurally acceptable. Durable gross margins provide room to invest in commercialization and absorb SG&A while creating a clearer path to operating leverage if revenue growth resumes, supporting long-term viability.
Negative Factors
Persistent negative cash flow
Chronic negative operating and free cash flows mean the business consumes capital rather than generates it, increasing reliance on external financings. Over 2–6 months this elevates execution risk: commercialization efforts require cash, and sustained burn pressures the balance sheet and increases dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin sustainability
Consistent mid-40% gross margins indicate the company’s product and service economics are structurally acceptable. Durable gross margins provide room to invest in commercialization and absorb SG&A while creating a clearer path to operating leverage if revenue growth resumes, supporting long-term viability.
Read all positive factors
BioLargo (BLGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$47.77M
Dividend YieldN/A
Average Volume (3M)570.01K
Price to Earnings (P/E)―
Beta (1Y)-0.37
Revenue Growth-41.57%
EPS Growth-345.83%
CountryUS
Employees40
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)-0.01
Shares Outstanding319,750,850
10 Day Avg. Volume632,227
30 Day Avg. Volume570,010
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.10
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-3.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$4.90M
BioLargo Business Overview & Revenue Model
Company Description
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater tre...
How the Company Makes Money
BioLargo makes money primarily through a mix of (1) product sales, (2) engineering and technical service revenue, and (3) technology commercialization arrangements (where available) such as licensing, distribution, or other partner-based channels....
BioLargo Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The call balanced notable commercialization and validation milestones (Clyra launch and clinical data, AEC municipal install with EPA monitoring, Cellinity MOUs and technology validation, service revenue doubling, and preserved cash) against material near-term financial challenges (2025 revenue decline to $7.8M, $15.2M net loss, a booked credit loss, Pooph license termination and litigation, and diminished shareholders' equity). Management emphasizes transition from development to commercialization and several near-term catalysts for 2026, but the significant 2025 financial deterioration and ongoing legal/partner risks temper the outlook.Positive Updates
Clyra Medical Commercial Launch and Clinical Validation
ViaCLYR (Clyra Medical) is now in commercial stage with FDA 510(k) clearance, an exclusive distribution agreement with Advanced Solution, and the first commercial stocking order shipped and paid. Strong clinical data was presented at the 48th Annual Boswick Symposium. Recent capital infusion of $1.7M (received in the last few weeks) positions Clyra for revenue growth; direct investments into Clyra over the past ~14 months total about $7.5M, with BioLargo contributing ~ $1.7M over the last 2 years and insiders (CEO and Chairman) contributing ~ $320k.
Negative Updates
Significant Financial Loss and Revenue Decline
Reported 2025 revenue declined to $7.8M and the company recorded a net loss of $15.2M. Management noted a material reduction in revenue (~$3.9M) that materially contributed to the year-over-year decline.
Read all updates
Q4-2025 Updates
Positive
Negative
Clyra Medical Commercial Launch and Clinical Validation
ViaCLYR (Clyra Medical) is now in commercial stage with FDA 510(k) clearance, an exclusive distribution agreement with Advanced Solution, and the first commercial stocking order shipped and paid. Strong clinical data was presented at the 48th Annual Boswick Symposium. Recent capital infusion of $1.7M (received in the last few weeks) positions Clyra for revenue growth; direct investments into Clyra over the past ~14 months total about $7.5M, with BioLargo contributing ~ $1.7M over the last 2 years and insiders (CEO and Chairman) contributing ~ $320k.
Read all positive updates
Company Guidance
Management guided that 2026 should be an inflection/“transformative” year with multiple catalysts converging: an accelerated national commercial rollout for Clyra Medical’s FDA 510(k)-cleared ViaCLYR (exclusive distributor access to thousands of hospitals, first stocking order shipped and paid), critical validation data expected from the AEC Lake Stockholm municipal installation under a 12‑month EPA/NJDEP monitoring program, Cellinity moving MOUs toward a first definitive joint‑venture to build gigafactories, and ONM pursuing new partnerships. They gave many metrics: Clyra received a $1.7M capital infusion (about $7.5M total direct Clyra investments over the past 14 months; BioLargo contributed ≈$1.7M over two years and Dennis/CEO Steve Harrison personally invested ≈$320k), BioLargo retains 49%–100% ownership in subsidiaries and a 6% royalty on sales, Cellinity targets a ~$1 trillion energy storage market projected to grow 6×–7× over 15 years and forecasts ~ $80–90M annual net operating income per gigafactory on ≈$170M capex, and project sizes discussed ranged from ~$0.5M–$2.5M up to $5M–$10M and now bidding in the $20M–$25M+ range. On corporate financials they reiterated 2025 results (revenues down to $7.8M, net loss $15.2M, stockholders’ equity $1.5M, cash $3.9M), service revenues roughly doubled (≈$1M to ≈$2M), they booked a ~$3.9M credit loss tied to the Pooph situation (Pooph owed $3.85M and was revoked; Pooph had >60,000 Amazon reviews), the Lincoln Park ATM expired with no renewal planned though management intends to pursue a similar facility, and they emphasized maintaining liquidity and avoiding toxic debt.BioLargo Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.76M | 17.78M | 12.23M | 5.88M | 2.53M |
| Gross Profit | 3.41M | 7.85M | 6.15M | 2.86M | 1.10M |
| EBITDA | -14.55M | -4.06M | -4.19M | -5.10M | -6.70M |
| Net Income | -11.78M | -2.40M | -3.50M | -4.50M | -7.38M |
Balance Sheet | |||||
| Total Assets | 8.31M | 10.51M | 8.21M | 4.86M | 3.02M |
| Cash, Cash Equivalents and Short-Term Investments | 3.88M | 3.55M | 3.54M | 1.85M | 962.00K |
| Total Debt | 3.51M | 2.55M | 1.70M | 1.47M | 1.13M |
| Total Liabilities | 6.79M | 4.46M | 4.00M | 2.85M | 2.09M |
| Stockholders Equity | 4.04M | 8.85M | 6.84M | 4.88M | 4.65M |
Cash Flow | |||||
| Free Cash Flow | -8.34M | -4.44M | -2.84M | -3.03M | -3.97M |
| Operating Cash Flow | -8.30M | -3.21M | -2.37M | -2.76M | -3.94M |
| Investing Cash Flow | 435.00K | -1.32M | -478.00K | -271.00K | -34.00K |
| Financing Cash Flow | 8.22M | 4.44M | 4.66M | 3.96M | 4.23M |
BioLargo Technical Analysis
Negative
0.19
Price Trends
0.17
Negative
0.17
Negative
0.18
Negative
Market Momentum
>-0.01
Positive
36.94
Neutral
31.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.17, and above the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.94 is Neutral, neither overbought nor oversold. The STOCH value of 31.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.
BioLargo Risk Analysis
BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLargo Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $626.95M | 9.44 | 6.06% | 3.81% | -5.05% | 35.01% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | $1.41B | -1.41 | -29.85% | 8.27% | -7.81% | -334.15% | |
52 Neutral | $617.33M | -4.74 | -99.73% | ― | -9.75% | -386.63% | |
48 Neutral | $185.10M | -2.83 | -28.62% | 7.12% | -49.82% | -195.74% | |
44 Neutral | $47.77M | -4.80 | -174.59% | ― | -41.57% | -345.83% | |
40 Underperform | $10.69M | -1,208.74 | -97.45% | ― | -28.47% | 16.83% |
* Basic Materials Sector Average
BLGO
BioLargo
0.15
-0.09
-37.13%
FF
Futurefuel
4.22
0.40
10.62%
TROX
TRONOX
8.90
4.17
88.16%
RYAM
Rayonier Advanced Materials
9.16
4.40
92.44%
ASIX
AdvanSix
23.33
3.89
20.00%
ORGN
Origin Materials
1.97
-13.83
-87.53%
BioLargo Corporate Events
Business Operations and StrategyPrivate Placements and Financing
BioLargo Secures Flexible Equity Financing Agreement with Clearthink
Positive
Mar 25, 2026
On March 20, 2026, BioLargo, Inc. entered into a purchase agreement and a registration rights agreement with Clearthink Capital Partners, under which Clearthink committed to buy up to $10 million of BioLargo’s common stock over a 36‑mo...
Business Operations and StrategyRegulatory Filings and Compliance
BioLargo Issues Investor Presentation Under Regulation FD Disclosure
Neutral
Mar 5, 2026
On March 5, 2026, BioLargo, Inc. planned to present investor slide materials at a webcast conference at 9:00 a.m. Pacific Time and also published a press release the same day. The company emphasized that these materials and the related Form 8-K di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.